Biodexa Pharmaceuticals PLC BDRX
Annual
Quarterly
No annual revenue total was found in Biodexa Pharmaceuticals PLC's SEC filings.
Biodexa Pharmaceuticals PLC (BDRX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
225.82B
+3277.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BDRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Cardiff
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1643918
- Former names
- Midatech Pharma Plc (until Mar 27, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 29, 2026 | Jul 29, 2026 |
| 6-K | Current report (foreign issuer) | Jul 9, 2026 | Jul 9, 2026 |
All 731 Biodexa Pharmaceuticals PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.